Table 5 Statistical analysis for all and distant recurrences in the TransATAC validation cohort
From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
Score | Univariate | Multivariable comparisons | ||||||
|---|---|---|---|---|---|---|---|---|
CTS + signature vs CTS | CTS + signature | |||||||
LRχ2 | p Value | HR (95% CI) | C-index (SE) | ∆LRχ2 | p Value | HR (95% CI) | C-index (SE) | |
All recurrences (n = 271, AR = 55) | ||||||||
 CTS | 37.4 | < 0.001 | 1.94 (1.57–2.40) | 0.664 (0.020) | – | – | – | – |
 10-Year signature | 20.7 | < 0.001 | 1.85 (1.42–2.41) | 0.657 (0.029) | 5.7 | 0.017 | 1.42 (1.07–1.89) | 0.695 (0.023) |
 BCI | 25.0 | < 0.001 | 2.07 (1.54–2.77) | 0.679 (0.029) | 9.5 | 0.002 | 1.62 (1.19–2.21) | 0.711 (0.024) |
 RS | 11.1 | < 0.001 | 1.52 (1.21–1.91) | 0.607 (0.027) | 5.8 | 0.016 | 1.35 (1.07–1.71) | 0.683 (0.021) |
 ROR | 18.3 | < 0.001 | 1.77 (1.36–2.31) | 0.650 (0.030) | 6.0 | 0.014 | 1.42 (1.07–1.87) | 0.700 (0.024) |
 IHC4 | 14.4 | < 0.001 | 1.63 (1.28–2.10) | 0.629 (0.029) | 7.5 | 0.006 | 1.46 (1.12–1.91) | 0.696 (0.023) |
Distant recurrences (n = 271, DR = 41) | ||||||||
 CTS | 46.7 | < 0.001 | 2.25 (1.79–2.82) | 0.689 (0.019) | – | – | – | – |
 10-Year signature | 26.4 | < 0.001 | 2.24 (1.64–3.06) | 0.694 (0.029) | 8.5 | 0.004 | 1.65 (1.18–2.30) | 0.733 (0.023) |
 BCI | 34.0 | < 0.001 | 2.71 (1.91–3.84) | 0.726 (0.028) | 14.5 | < 0.001 | 2.03 (1.40–2.95) | 0.754 (0.023) |
 RS | 10.7 | < 0.001 | 1.58 (1.23–2.03) | 0.616 (0.029) | 5.1 | 0.024 | 1.38 (1.06–1.79) | 0.707 (0.020) |
 ROR | 21.3 | < 0.001 | 2.05 (1.50–2.79) | 0.680 (0.031) | 7.5 | 0.006 | 1.58 (1.14–2.21) | 0.736 (0.024) |
 IHC4 | 17.9 | < 0.001 | 1.87 (1.41–2.49) | 0.658 (0.031) | 9.8 | 0.002 | 1.68 (1.22–2.31) | 0.731 (0.023) |